Université Laval

Pila Pharma's XEN-D0501 Shows Promise in Preclinical Abdominal Aortic Aneurysm Study

4 months ago

• Pila Pharma's XEN-D0501, a TRPV1 antagonist, significantly reduced abdominal aorta aneurysm growth in mice by over 50% compared to placebo, demonstrating preclinical proof-of-concept. • XEN-D0501 has shown good tolerability in Phase 2a trials involving individuals with obesity and type 2 diabetes, enhancing insulin response and reducing cardiovascular biomarkers. • A Phase 2a trial (PP-CT03) is planned to identify the maximum tolerable dose of XEN-D0501 in obese and type 2 diabetic patients, evaluating its safety profile over a 3-month treatment period. • While early data are promising, researchers urge caution, emphasizing the need for more quality human data to fully understand XEN-D0501's potential in treating metabolic and cardiovascular diseases.

VALBIOTIS Announces Interim Financial Statements and Strategic Developments

7 months ago

VALBIOTIS has published its interim financial statements, highlighting significant progress in its product launches, clinical trials, and strategic reorganization. The company is focusing on marketing its dietary supplements, with plans for future launches and international expansion. Financial details reveal a solid cash position and strategic investments in sales and marketing.